NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1×1 Meetings on Thursday, April 24, 2025
CARMEL, Ind., April 15, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or…
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic…
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
– BRTX-100 is the first and only stem cell product candidate cleared…
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
--- The United States FDA Approves the Initiation for Phase II Efficacy…
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreichs Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting…
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
December 30, 2024 16:05 ET | Source: Inotiv, Inc. WEST LAFAYETTE, Ind.,…
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million
December 23, 2024 16:05 ET | Source: Inotiv, Inc. WEST LAFAYETTE, Ind.,…
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz
** IND submitted to the FDA showing significantly improved patient condition when…
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in…
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE…